https://www.businesswire.com/news/home/20230108005070/en/Genexine-to-Present-Final-Phase-2-Clinical-Data-on-Its-Cervical-Cancer-Program-Showing-a-35.0-Overall-Response-Rate-and-Provide-a-Corporate-Overview-During-JP-Morgan-Conference
0
0
1/8/23 at 5:05pm
Organization
Business Wire
51 words
0
Comments
Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel bio
You are the first to view
Create an account
or login to join the discussion